Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from OCEANS, a Phase III study evaluating Avastin® (bevacizumab) in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer...
Exelixis, Inc. (NASDAQ:EXEL) reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial...
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today presented results at the Annual Meeting of the American Society for Clinical Oncology (ASCO) from a Phase 2 single agent clinical trial of ganetespib in advanced non-small cell lung cancer (NSCLC) that showed promising clinical activity in patients with progressive disease...
Incyte Corporation (Nasdaq:INCY) announced today results from the global, pivotal Phase III clinical program of ruxolitinib (INCB18424 or INC424) in patients with myelofibrosis (MF) at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting. MF is a potentially life-threatening blood cancer characterized by bone marrow failure, enlarged spleen (splenomegaly) and debilitating symptoms...
Studies Report Results Defining New Standards Of Clinical Cancer Care
6/06/2011
Studies describing progress in establishing new treatment standards against advanced cancers, specifically melanoma and neuroblastoma, were released today at a press briefing at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). "The studies presented today highlight tremendous advances in the treatment of metastatic melanoma," said Lynn Schuchter, MD, the C...
Practice-Changing Cancer Trial Shows Additional Radiation Decreases Cancer Recurrence, Canada
6/06/2011
A Canadian-led clinical trial has found that additional radiation treatment improves disease-free survival in women with early breast cancer and reduces the risk of cancer recurrence, a finding that could change the standard treatment for this group of patients. The trial was led by the NCIC Clinical Trials Group, which is funded by the Canadian Cancer Society...
A large international Canadian-led clinical trial investigating a new way to prevent breast cancer in women at increased risk of developing the disease has found that the drug exemestane reduces this risk by 65 per cent compared with placebo...
Targeted Cancer Therapy Kills Prostate Tumor Cells
6/06/2011
A new targeted therapy for prostate cancer halts tumor growth in animals with advanced prostate cancer that is resistant to hormone therapy, a new study finds. The results will be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston...
Bayer Healthcare today announced that the Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial evaluating Bayer's investigational compound Alpharadin (radium-223 chloride), which is exclusively licensed from Algeta ASA, in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases met its primary endpoint by significantly improving overall survival...
Flaxseed No Cure For Hot Flashes During Breast Cancer Or Menopause
6/06/2011
Flaxseed provides no benefit in easing hot flashes among breast cancer patients and postmenopausal women, according to a Mayo Clinic and North Central Cancer Treatment Group (NCCTG) study...